Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

The past year has seen the rise of myriad weight-loss drugs that are getting ... In America, the trend of increasing obesity has stalled and even slightly reversed. In 2021-2023, 40 per cent ...

In this photo is a Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. (Photographer: Shelby Knowles/Bloomberg) The anti-obesity drug Zepbound ...

For the first time in a decade, U.S. obesity rates have begun to decline, raising hopes that the nation may be turning a ...

For the first time in a decade, the United States is seeing a slight decline in obesity rates. A new study published in ... the rise in usage of weight loss drugs like semaglutide is contributing ...

(Those are slightly higher shares than the estimate from the Center s for Disease Control and Prevention, which says around 40% of U.S. adults had obesity from 2021 ... the new drugs' true impact.

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Maggie O’Neill is a health writer and reporter based in New York who specializes in covering medical research and emerging wellness trends, with a focus on cancer and addiction. Prior to her ...

in New York City. Gary Hershorn/Getty Images Last year, poison control centers across the country reported spikes in calls related to overdoses of anti-obesity medications. Authorities attributed ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In July 2024, Joseph Zucchi, PA-C, MPAS, wrote about how ...